APA (7th ed.) Citation

Y, N., N, Y., K, N., H, U., S, M., M, O., . . . T, F. (2026). Nivolumab for unresectable cutaneous epithelial malignancies: An open-label, single-arm, multi-centre, phase II trial (NMSC-PD1). BMC cancer, 26(1), . https://doi.org/10.1186/s12885-026-15829-2

Chicago Style (17th ed.) Citation

Y, Nakamura, et al. "Nivolumab for Unresectable Cutaneous Epithelial Malignancies: An Open-label, Single-arm, Multi-centre, Phase II Trial (NMSC-PD1)." BMC Cancer 26, no. 1 (2026). https://doi.org/10.1186/s12885-026-15829-2.

MLA (9th ed.) Citation

Y, Nakamura, et al. "Nivolumab for Unresectable Cutaneous Epithelial Malignancies: An Open-label, Single-arm, Multi-centre, Phase II Trial (NMSC-PD1)." BMC Cancer, vol. 26, no. 1, 2026, https://doi.org/10.1186/s12885-026-15829-2.